Welcome to our dedicated page for Glycomimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on Glycomimetics stock.
GlycoMimetics, Inc. develops glycobiology-based therapies for cancers, including acute myeloid leukemia, and inflammatory diseases. Its platform uses specialized chemistry to discover small molecule glycomimetics that alter carbohydrate-mediated cell recognition.
Company news centers on uproleselan clinical data in AML, presentations of trial results, regulatory-path updates, and pipeline references including GMI-1687. Recurring corporate developments also include material agreements, shareholder voting matters, capital-structure disclosures, governance updates, strategic review and restructuring activity, and operating and financial results.
GlycoMimetics, Inc. (Nasdaq: GLYC) is set to host a conference call on November 6, 2020, at 8:30 a.m. ET to discuss its third quarter financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466, with a participant code of 3073766. The company is focused on developing glycomimetic drugs for unmet medical needs, with late-stage programs including uproleselan, currently in a Phase 3 trial for AML, and rivipansel for SCD. A webcast replay of the call will be available for 30 days on their website.
GlycoMimetics, Inc. (Nasdaq: GLYC) has announced new data from post hoc analyses of the Phase 3 RESET study, indicating that pediatric patients treated with rivipansel within 30 hours of pain onset showed significant improvements in discharge readiness and reduced IV opioid use compared to placebo. Key metrics include a median time to readiness for discharge reduced by 29.3 hours and time to discharge reduced by 23.2 hours. Additionally, rivipansel demonstrated a favorable safety profile, prompting GlycoMimetics to engage with the FDA regarding future steps in its development for acute vaso-occlusive crises (VOC).
GlycoMimetics, Inc. (Nasdaq: GLYC) has received Rare Pediatric Disease designation from the FDA for rivipansel, aimed at treating sickle cell disease in patients 18 and younger. This recognition underlines the urgent need for effective treatments for pediatric patients suffering from this serious condition. GlycoMimetics holds global rights for rivipansel and is in discussions with the FDA regarding regulatory pathways for approval. The company also plans to present comprehensive data from its Phase 3 RESET program at upcoming medical meetings.